Published in

American Society of Hematology, Blood, 23(142), p. 2029-2033, 2023

DOI: 10.1182/blood.2023020855

Links

Tools

Export citation

Search in Google Scholar

TP53 status and impact on AML prognosis within the ELN 2022 risk classification

Journal article published in 2023 by Shaun Fleming, Xavier Cheng-Hong Tsai, Rhiannon Morris ORCID, Hsin-An Hou, Andrew H. Wei ORCID
Distributing this paper is prohibited by the publisher
Distributing this paper is prohibited by the publisher

Full text: Unavailable

Red circle
Preprint: archiving forbidden
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Abstract This study reports the following: (1) frequency of TP53 comutation within each component of the European LeukemiaNet 2022 acute myeloid leukemia risk classification, (2) relevance of TP53 mutated variant allelic fraction <10%, (3) prognostic impact of −7, −5/del(5q), −17/abn(17p), complex karyotype/monosomal karyotype, or myelodysplasia-related gene mutations with/without mutated TP53.